Profound Medical Unveils AI BPH Module, New Clinical Data
Perioperative data from the CAPTAIN randomized trial indicated lower blood loss, shorter length of stay, reduced post‑operative pain, and...
First Patient Dosed in Innocare’s Prurigo Nodularis Trial
InnoCare has dosed the first patient in a global Phase II trial of its oral TYK2 inhibitor, soficitinib (ICP-332),...
Silexion Completes SIL204 Toxicology for Pancreatic Cancer
Two-species toxicology for Silexion’s siRNA candidate SIL204 reported no systemic organ toxicity, clearing a key preclinical gate and keeping...
Tempest Closes Up To $8.35M Registered Direct Offering
Tempest Therapeutics closed a registered direct offering of 1,172,414 shares at $3.625 per share for approximately $4.25 million in...
Hutchmed Highlights Data for ESMO Asia, ASH 2025 Meetings
No efficacy or safety figures were disclosed ahead of the meetings, but HUTCHMED will take a broad slate of...
First Patient Dosed in Phase II Prurigo Nodularis Trial
InnoCare has dosed the first patient in a global Phase II study of Soficitinib (ICP-332), a selective TYK2 inhibitor,...
Dipharma’s Novel Approach to Nitrosamine Detection in APIs
Dipharma reports a new analytical approach that combines 15N‑enriched nitrosating reagents with 15N NMR readout to selectively detect and...
Hutchmed Highlights New Clinical Data for 2025 ESMO & ASH
HUTCHMED will take a multi-asset slate to ESMO Asia and ASH in early December, flagging new and updated readouts...
Xenon to Present New Azetukalner Epilepsy Data at AES 2025
A ≥48-month interim analysis from Xenon’s ongoing seven-year X-TOLE open-label extension will be featured at AES 2025, focusing on...
Scilex Holding Completes Equity Financing in Datavault AI
Scilex has exercised a pre-funded warrant for 263,914,094 shares of Datavault AI, a stake valued at approximately $583.3 million...